AbbVie vs Johnson & Johnson at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | ABBV | JNJ |
|---|---|---|
| Market cap | $457.23B | $649.68B |
| Price | $258.15 | $265.77 |
| P/E ratio (TTM) | 95.29 | 18.74 |
| P/B ratio (MRQ) | 0 | 6.16 |
| P/S ratio (TTM) | 6.58 | 5.33 |
| Revenue growth (1Y) | 8.57% | 6.05% |
| Return on equity (TTM) | -129.24% | 32.87% |
| Return on invested capital (TTM) | 21.13% | 16.26% |
| Gross margin (TTM) | 73.70% | 75.17% |
| Net margin (TTM) | 5.79% | 21.48% |
| Dividend yield (TTM) | 2.68% | 2.01% |
How they differ
Johnson & Johnson is the larger company at $649.68B versus $457.23B — about 1.4x the size.
On trailing earnings, Johnson & Johnson is the cheaper of the two at 18.74 against 95.29 for AbbVie.
On sales, Johnson & Johnson is the cheaper of the two at 5.33 against 6.58 for AbbVie.
AbbVie leads on revenue growth over the past year, 8.57% against 6.05%.
AbbVie leads on return on invested capital, 21.13% against 16.26%.
Johnson & Johnson leads on gross margin, 75.17% against 73.70%.
AbbVie offers the higher yield at 2.68% against 2.01%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving AbbVie or Johnson & Johnson.